Viking Therapeutics' weight-loss drug data makes company takeover target marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Operator: Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
New clinical trial results from El Lilly suggest its Type 2 diabetes and weight-loss drug, tirzepatide, could upend the incipient market for MASH treatments.
72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile.